SCHEDULE: EcoR1 Capital Discloses 2.9% Stake in Xencor Inc.

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 2.9% beneficial ownership stake in Xencor Inc.

Summary

• EcoR1 Capital, LLC, its affiliate EcoR1 Capital Fund Qualified, L.P., and Oleg Nodelman have reported a combined beneficial ownership of 2,183,000 shares of Xencor Inc. common stock.
• This holding represents approximately 2.9% of the total outstanding common stock of Xencor Inc., based on 71,141,596 shares outstanding as of May 1, 2026.
• The reporting persons hold shared voting and dispositive power over these shares.
• The filing confirms that these securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure indicating institutional support without active management intervention.

Positives

• The investment reflects institutional interest in Xencor Inc. from a specialized healthcare-focused investment firm.

Negatives

• The stake remains below the 5% threshold that typically triggers more rigorous disclosure requirements, indicating a passive investment position.

Risks

• Market volatility affecting the valuation of biotechnology holdings.
• Regulatory and clinical trial risks inherent to the pharmaceutical industry.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's business, as it is a passive ownership disclosure.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by specialized healthcare investment firms like EcoR1 Capital are common in the biotech sector, often signaling long-term confidence in a company's clinical pipeline or platform technology.

Comparison to Industry Standards

• The 2.9% stake is a standard position size for institutional investors maintaining a passive, non-controlling interest in mid-cap biotechnology firms.
• The filing adheres to standard SEC regulatory requirements for passive investors under Rule 13d-1.

Stakeholder Impact

• Shareholders may view the presence of a specialized healthcare investor as a positive indicator of institutional validation.

Next Steps

• The reporting persons will continue to monitor their investment in the ordinary course of business.

Key Dates

Keywords

Xencor, XNCR, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Biotechnology, Institutional Ownership